3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Completed
1
Approved for marketing
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
11
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
HER2-positive Breast Cancer
2
Stomach Neoplasms
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Meningeal Carcinomatosis
1
Hemangiosarcoma
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Trastuzumab
8
pyrotinib
6
pertuzumab
4
Docetaxel
3
Capecitabine
3
tucatinib
2
Paclitaxel
2
Neoadjuvant Therapy
2
trastuzumab deruxtecan
1
neratinib
1
inavolisib
1
Taxoids
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Genetic Testing
1
Drug Therapy
1
Carboplatin
1
Blood Specimen Collection
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
HER2-positive Breast Cancer
×
tucatinib
×
Clear all
NCT07413939
2026-05-11
BREnnA
Hoffmann-La Roche
Phase 2/3
Recruiting
650 enrolled
NCT05955170
2025-03-27
TUC-TOC
Institut Curie
Phase 2
Recruiting
66 enrolled